title: Manufacturing of recombinant adeno-associated viral vectors for clinical trials.
abstract: The ability to elicit robust and long-term transgene expression in vivo together with minimal immunogenicity and little to no toxicity are only a few features that make recombinant adeno-associated virus (rAAV) vectors ideally suited for many gene therapy applications. Successful preclinical studies have encouraged the use of rAAV for therapeutic gene transfer to patients in the clinical setting. Nevertheless, the use of rAAV in clinical trials has underscored the need for production and purification systems capable of generating large amounts of highly pure rAAV particles. To date, generating vector quantities sufficient to meet the expanding clinical demand is still a hurdle when using current production systems. In this chapter, we will provide a description of the current methods to produce clinical grade of rAAV under current good manufacturing practice (cGMP) settings.
authors.affiliation: Department of Pediatrics, Powell Gene Therapy Center, University of Florida , Gainesville, Florida, USA.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Clément
authors.affiliation: Bamboo Therapeutics Inc. , Chapel Hill, North Carolina, USA.
authors.forename: Joshua C
authors.initials: JC
authors.lastname: Grieger